Science Hub

Synopsis of the original article *'CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries'*

Mosenzon O, et al. Cardiovasc Diabetol. 2021;20:154.

Synopsis created and reviewed by Novo Nordisk

Trial numbers: NCT03786406, NCT03811288

Introduction



*Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors
CV, cardiovascular; CVD, cardiovascular disease; T2D, type 2 diabetes

Methods



CVD prevalence (weighted by diabetes prevalence in each country) **was estimated for:**

- The overall sample
- Participating countries

Country-specific odds ratio for **CVD prevalence was adjusted for:**

- Demographic parameters
- Clinical parameters

CVD, cardiovascular disease; KSA, Kingdom of Saudi Arabia; T2D, type 2 diabetes

Results

CAPTURE overall sample



Prevalence



*Data are reported as median (interquartile range)
CI, confidence interval; CVD, cardiovascular disease; T2D, type 2 diabetes

GLA use (with demonstrated CV benefit) was similar in participants with and without CVD



CV, cardiovascular; CVD, cardiovascular disease; GLAs, glucose-lowering agents

Conclusion

2019

One in three adults with T2D in CAPTURE had diagnosed CVD

Low use of GLAs with demonstrated CV benefit in adults with established CVD

Suggested that

Most were not managed as per contemporary diabetes and cardiology guidelines

CV, cardiovascular; CVD, cardiovascular disease; GLAs, glucose-lowering agents; T2D, type 2 diabetes